An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.
Sarah Maxwell, Audio Journal of Oncology:
“An exciting, new immunotherapy treatment for multiple myeloma, was under discussion at the 2024 American Association for Cancer Research Annual Meeting, held in San Diego. It was with a drug that targets not one but two cells to fight the disease.
The agent, linvoseltamab, is a B-cell maturation antigen-targeted, T-cell-engaging, bispecific antibody. A multi-center international study, reported at the conference that patients with relapsed or refractory multiple myeloma, had robust clinical benefit from treatment with the drug. And that included those in difficult-to-treat subgroups.
After giving his talk in San Diego, lead author Sundar Jagannath, Director of the Center of Excellence for Multiple Myeloma, at Mount Sinai in New York, gave the Audio Journal of Oncology more details on the therapeutic benefits the drug offers. He began by talking about where this new approach fits into the landscape and history of treatments for multiple myeloma:
Audio Journal of Oncology interview with: Sundar Jagannath MBBS, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.
IN: I’ve been in the field of multiple myeloma….…
OUT: ….in New York. I’m Peter Goodwin.
15:43”
AACR Abstract Title:
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
https://www.abstractsonline.com/pp8/#!/20272/presentation/11419
